Conversion therapy in patients with metastatic gastric cancer
10.3760/cma.j.cn113855-20211119-00672
- VernacularTitle:转移性胃癌的转化治疗
- Author:
Chao WANG
1
;
Zhidong GAO
;
Kai SHEN
;
Zhanlong SHEN
;
Kewei JIANG
;
Bin LIANG
;
Jing ZHOU
;
Yingjiang YE
Author Information
1. 北京大学人民医院胃肠外科，北京 100044
- Keywords:
Stomach neoplasms;
Lymphatic metastasis;
Prognosis;
Conversion therapy
- From:
Chinese Journal of General Surgery
2022;37(8):561-566
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate clinicopathological characteristics and efficacy of conversion therapy in patients with metastatic gastric cancer.Methods:The clinicopathological and follow-up data of metastatic gastric cancer patients at the Department of Gastrointestinal Surgery of Peking University People's Hospital from Jan 2018 to Jun 2021 were retrospectively studied. Multivariate Logistic regression analysis was used to identify independent characteristics for pathological complete response (PCR). The influence of stage of metastatic gastric cancer and pathological response on prognosis were analyzed by Kaplan-Meier curve.Results:A total of 31 patients were enrolled, and 13 tumors located at the cardia or fundus, 8 at body, other 10 at pylorus or antrum . Baseline CT evaluation showed retroperitoneal lymph node metastasis in 10 cases, intraperitoneal metastasis in 10 cases, liver metastasis in 2 cases, adrenal and splenic metastasis in 1 case respectively, and multiple metastasis in 5 cases. After conversion therapy, 8 (26%) cases had pathological T0, 16 cases (52%) had pathological N0 and 7 cases (22%) had pathological complete response. Multivariate Logistic regression analysis showed retroperitoneal lymph node metastasis ( OR: 20.082, 95% CI: 2.141-188.315, P=0.009) was the only independent risk factor of PCR. Meanwhile, Kaplan-Meier curve showed pT0 improved disease-free survival significantly ( P=0.021). Conclusions:Metastatic gastric cancer patients with retroperitoneal lymph node metastasis alone had a tolerable conversion therapy effect. pT0 is a significant factor in improving prognosis.
